| Drug Name |
Erlotinib |
| Drug ID |
BADD_D00800 |
| Description |
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders. |
| Indications and Usage |
For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01EB02 |
| DrugBank ID |
DB00530
|
| KEGG ID |
D07907
|
| MeSH ID |
D000069347
|
| PubChem ID |
176870
|
| TTD Drug ID |
D07POC
|
| NDC Product Code |
70771-1521; 63304-096; 63850-7566; 68382-913; 63304-095; 0093-7663; 70771-1522; 68382-914; 59923-725; 59923-726; 0093-7664; 0093-7662; 68382-915; 70771-1523; 68554-0052; 63304-135; 59923-727 |
| Synonyms |
Erlotinib Hydrochloride | Hydrochloride, Erlotinib | Erlotinib HCl | HCl, Erlotinib | OSI-774 | OSI 774 | OSI774 | CP 358774 | 358774, CP | CP 358,774 | 358,774, CP | CP-358,774 | CP358,774 | CP-358774 | CP358774 | 11C-erlotinib | 11C erlotinib | Erlotinib | N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine | Tarceva |
